Healthcare -
Drug Manufacturers - General - NASDAQ - US
$ 289.69
-1.6 %
$ 156 B
Market Cap
38.27
P/E
1. INTRINSIC VALUE
Balance Sheet
Amgen Inc.
| Current Assets | 29 B |
| Cash & Short-Term Investments | 12 B |
| Receivables | 6.78 B |
| Other Current Assets | 10.3 B |
| Non-Current Assets | 62.8 B |
| Long-Term Investments | 0 |
| PP&E | 6.54 B |
| Other Non-Current Assets | 56.3 B |
| Current Liabilities | 23.1 B |
| Accounts Payable | 19.5 B |
| Short-Term Debt | 3.55 B |
| Other Current Liabilities | 0 |
| Non-Current Liabilities | 62.9 B |
| Long-Term Debt | 56.5 B |
| Other Non-Current Liabilities | 6.31 B |
EFFICIENCY
Earnings Waterfall
Amgen Inc.
| Revenue | 33.4 B |
| Cost Of Revenue | 12.9 B |
| Gross Profit | 20.6 B |
| Operating Expenses | 13.3 B |
| Operating Income | 7.26 B |
| Other Expenses | 3.17 B |
| Net Income | 4.09 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Amgen Inc.
| Net Income | 4.09 B |
| Depreciation & Amortization | 5.59 B |
| Capital Expenditures | -1.1 B |
| Stock-Based Compensation | 0 |
| Change in Working Capital | 0 |
| Others | 1.81 B |
| Free Cash Flow | 10.4 B |
Wall Street Analysts Price Targets
Amgen Inc.
Wall Street analysts predict an average 1-year price target for AMGN of $326 , with forecasts ranging from
a
low of
$215 to a high of $405 .
AMGN Lowest Price Target
Wall Street Target
215 USD
-25.78%
AMGN Average Price Target
Wall Street Target
326 USD
12.38%
AMGN Highest Price Target
Wall Street Target
405 USD
39.80%
4. DIVIDEND
ANALYSIS
0.86%
DIVIDEND YIELD
2.38 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Amgen Inc.
Sold
0-3 MONTHS
23.8 M USD 6
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
663 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
3 Dividend Stocks to Buy and Hold for the Next Decade
What should investors do when stocks are tanking over the short term? Probably the best answer is to think long term.
fool.com
- 2 weeks ago
2 Dividend Stocks to Buy Hand Over Fist in April
One factor that keeps some investors away from healthcare stocks is the sector's dearth of generous and reliable dividend payers. This stands to reason, as nearly every stage of drug development and marketing is resource- and capital-intensive, and as a result, cash can be in short supply.
fool.com
- 2 weeks ago
AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication
The FDA approves Amgen's Uplizna as the first and only drug for the treatment of immunoglobulin G4-related disease.
zacks.com
- 2 weeks ago
Live Nasdaq Composite: FIVE Falls, AZN and PEP Rise From Tariff Ashes
The markets have succumbed to the tariff-fueled selling pressure, and there is nowhere to hide. President Trump’s tariff plan is intensifying the trade war. The Dow Jones Industrial is spiraling by over 1,160 points, while the tech-laden Nasdaq Composite is suffering a 4.3% drop. Meanwhile, the S&P 500 is on track for its single worst performance in two years. No sector of the economy has been left unscathed, and all of them are currently trading in the red. Consumer discretionary stocks are reeling by 5%, while the energy and technology sectors are each seeing declines of 5%. Several of the Magnificent 7 stocks are seeing declines in the ballpark of 6%, including Tesla (Nasdaq: TSLA), Meta (Nasdaq: META) and Amazon (Nasdaq: AMZN). New issue Newsmax (NYSE: NMAX) couldn’t have picked a worse day to ring the opening bell on the NYSE with the stock plummeting by a double-digit percentage. AstraZeneca (Nasdaq: AZN) is bucking today’s downward trend and gaining 2.3% on the heels of FDA approval for one of its drugs. AZN is one of the stocks ignoring the tariff headlines today. PepsiCo (Nasdaq: PEP) is gaining 2% on the heels of a report in the Wall Street Journal that it is trying to recapture lost market share after “losing focus.” Also, PepsiCo is partnering with sandwich shop Subway for a Doritos inspired sub sandwich. Here’s a look at the performance as of morning trading: Dow Jones Industrial Average: Down 1,166.15 (-2.76%) Nasdaq Composite: Down 768.16 (4.33%) S&P 500: Down 181.42 (-3.20%) Key Points The stock market is taking, including a 4% decline in the Nasdaq Composite. The Dow Jones Industrial Average is in freefall, losing over 1,100 points. There are rare gainers today, including AZN and PEP. Market Movers We were able to uncover some gainers in today’s market sell-off. Citi analysts identified a couple of discount retailer stocks that could withstand the trade wars, including TJX Companies (NYSE: TJX) and Ross Stores (Nasdaq: ROST), the former of which is up 2.2% on the day. Potato company Lamb Weston (NYSE: LW) is seeing gains of 7% on the heels of better-than-expected quarterly results and a steady outlook. Pharma stocks Gilead Sciences, Amgen and Vertex Pharma are seeing gains between 1% and 1.5% on the day. The post Live Nasdaq Composite: FIVE Falls, AZN and PEP Rise From Tariff Ashes appeared first on 24/7 Wall St..
https://247wallst.com
- 2 weeks ago
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts
Amgen (AMGN) concluded the recent trading session at $310.09, signifying a +1.44% move from its prior day's close.
zacks.com
- 2 weeks ago
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst trading days in years, and almost no sector of the economy was spared.
fool.com
- 2 weeks ago
UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
Breakthrough CD19+ B-Cell Targeted Therapy Delivered an 87% Reduction in the Risk of Flares Versus Placebo UPLIZNA Shown to Deliver Corticosteroid-Free, Flare-Free, Complete Remission for Patients in the MITIGATE Trial Advances Amgen's Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG THOUSAND OAKS, Calif. , April 3, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD).
prnewswire.com
- 2 weeks ago
US FDA approves expanded use of Amgen's rare disease drug
The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares in patients with a rare immune system-related condition, the regulator said on Thursday.
reuters.com
- 2 weeks ago
Final Trades: Amgen, Sabra Health Care and Kinsale Capital Group
(OPTIMIZED VIDEO SPECIFIC DESCRIPTION)
youtube.com
- 2 weeks ago
Got $5,000? These 3 Nasdaq Stocks Are Dirt Cheap Buys Right Now
As of Monday, the Nasdaq Composite index had tumbled more than 11% since the start of the year. The outlook for the economy is worrisome, as trade wars and promised tariffs could lead to disaster for many businesses.
fool.com
- 2 weeks ago
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
cnbc.com
- 2 weeks ago
GILD or AMGN: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Amgen (AMGN). But which of these two companies is the best option for those looking for undervalued stocks?
zacks.com
- 2 weeks ago
8. Profile
Summary
Amgen Inc. AMGN
COUNTRY
US
INDUSTRY
Drug Manufacturers - General
MARKET CAP
$ 156 B
Dividend Yield
0.86%
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Contact
One Amgen Center Drive, Thousand Oaks, CA, 91320-1799
https://www.amgen.com
IPO
Date
June 17, 1983
Employees
28000
Officers
Mr. Scott Skellenger
Senior Vice President & Chief Information Officer
Mr. Robert A. Bradway
Chairman, Chief Executive Officer & President
Dr. David M. Reese M.D.
Executive Vice President & Chief Technology Officer
Mr. Murdo Gordon
Executive Vice President of Global Commercial Operations
Mr. Matthew C. Busch
Chief Accounting Officer & Vice President of Finance
Mr. Esteban Santos
Executive Vice President of Operations
Dr. Howard Y. Chang M.D., Ph.D.
Senior Vice President of Global Research & Chief Scientific Officer
Justin G. Claeys
Vice President of Investor Relations
Mr. Jonathan P. Graham J.D.
Executive Vice President, General Counsel & Secretary
Mr. Peter H. Griffith
Executive Vice President & Chief Financial Officer